ReproNovo

📍 Lausanne, Switzerland🗓 Founded 2021👥 19 employees💰 Last funded Oct 2024
Biotechnology Research🌐 repronovo.com
Website LinkedIn
At ReproNovo, we are redefining whats possible in reproductive medicine and women’s health. We are advancing innovative therapeutic solutions for both male and female infertility, as well as pioneering treatment options for uterine conditions like adenomyosis, delivering meaningful change to patients worldwide. Our international team brings together deep expertise across reproductive medicine, drug development, regulatory strategy, and business development—with a proven track record of bringing multiple therapies to market. ReproNovo is backed by leading investors including Jeito Capital, AXA IM Alts, M Ventures, Ysios Capital, and ALSA Ventures. Headquartered in Lausanne, Switzerland, our primary development team is located in Copenhagen, Denmark, with an additional development site in Barcelona, Spain. Imprint ReproNovo S.A. Rue de Langallerie 11 1003 Lausanne, Switzerland E-Mail: info@repronovo.com Chief Executive Officer & Co-Founder: Jean Duvall Chief Scientific & Medical Officer & Co-Founder: Joan-Carles Arce Chief Financial Officer & Co-Founder: BingMei Hao
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Netherlands
1
Frequently asked questions
Who invested in ReproNovo?
ReproNovo has 1 investors on record on gritt.io, 1 mid-stage.
When did ReproNovo last raise funding?
The most recent investment in ReproNovo recorded on gritt.io was in October 2024.
When was ReproNovo founded?
ReproNovo was founded in 2021.
What industry is ReproNovo in?
ReproNovo operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ReproNovo based?
ReproNovo is headquartered in Lausanne, Switzerland.